| |
Digital transformation, AI, big data, and regulatory action—these four trends are shaping the healthcare industry. From new technologies to billion-dollar research funding, there are plenty of lucrative investment opportunities to be had. Learn more.
|
|
Today’s Big NewsAug 22, 2023 |
|
October 16-17 | Boston, MA
Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book your seat today and save $200!
|
|
| By Angus Liu Novartis is cutting another 103 jobs at its U.S. headquarters in New Jersey, where the pharma giant just recently executed a 285-person round of layoffs. |
|
|
|
By Max Bayer After complications with the CRO work behind Pfizer's Lyme disease shot, vaccine R&D chief Annaliesa Anderson, Ph.D., says that much fewer than the planned 18,000 participants will be recruited. |
By Andrea Park Much like a boy band moving on to its next gig, after more than half a decade leading Zimmer Biomet, Bryan Hanson is taking on the top spot at another medtech giant. |
By James Waldron After a six-month wait, Fulcrum Therapeutics’ sickle cell disease plans are back on track after the FDA lifted a hold on the biotech’s candidate. |
By Angus Liu A few weeks ago, Roche said a phase 3 study testing its RET inhibitor Gavreto in a type of thyroid cancer was not doable. Now, Eli Lilly has revealed that a similar trial of its Retevmo was not only feasible but positive. |
By Conor Hale After cutting costs earlier this year—including through a rolling wave of worldwide layoffs—Medtronic is starting off its 2024 fiscal year with reports of single-digit sales growth across each of its business areas. |
By Fraiser Kansteiner The FDA approved Ingrezza capsules to treat adult with chorea associated with Huntington’s disease. Ingrezza was first approved in tardive dyskinesia in 2017. With its second approval, the medication’s label now largely stacks up to Teva Pharmaceuticals’ Austedo. |
By Nick Paul Taylor The vultures are circling Aravive. Still reeling from a phase 3 flop, the cash-strapped biotech has “several weeks” to find a partner or funding—and is laying off 70% of its staff to preserve the little money it has left. |
By Andrea Park “The market for kitted NGS-based companion diagnostics has not developed as we expected," Mike McMullen, Agilent’s president and CEO, told investors this month. |
By Fraiser Kansteiner Problems with quality management, data integrity, expired raw materials and more have prompted the European Medicines Agency to put the kibosh on manufacturing at Serra Pamies’ Reus, Spain, facility. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
